Scientific Breakthroughs.

Transformative Medicines.

Life Science Investment Fund focused on the most promising new breakthrough drugs

meet aquilo

Bringing Dramatic Advances
in the Biotechnology Sector

Aquilo Capital invests in drug development companies that harness the power of cutting-edge science to address urgent medical needs. We employ deep sector expertise and a disciplined, value-oriented process to identify extraordinary biotech companies.

Biotech Investment Fund opportunities
EU Opportunities

Expanding European Opportunity

The unique evolution of research in the European landscape has created a scaffold for quality innovation, resilience, and the resources to deliver results efficiently


We Invest in Drug Development Companies *

We believe these investment opportunities offer both substantial risk-adjusted returns as well as paradigm-changing therapeutics for patients and for society.

industry veterans

Long History and Reputable Track Record

We have a long history and track record of achieving strong absolute return for our partners while investing in important new medicines for large unmet medical needs.

The Four Pillars

At Aquilo, Process Matters

Financial Strength logo1
Financial Strength
Long runway to prosecute development w/ independence from public equity market. Existing sources of revenue that help anchor a margin of safety
Innovative Platform logo2
Innovative Platform
Engine for innovation that enables ongoing creation of differentiated drugs. Source of business development activity to leverage external value creation
Broad Pipeline logo3
Broad Pipeline
Diversity of programs helps to diffuse concentrated risk, more shots on goal. Can drive significant pricing inefficiency with compelling early-stage programs
Pharma Partnership logo4
Pharma Partnerships
Source of non-dilutive capital that also helps to provide validation for platform technology. Enables innovator company to focus on core competencies in new drug discovery
The Aquilo advantages

We Employ Both a Hedged & Long-Only Strategy

We employ a long-only and volatility strategy and invests in companies operating in the drug development and biotechnology sectors.

Disciplined, Value- Oriented Process

We employ deep sector expertise and a disciplined, value-oriented process with the potential to improve the practice of medicine.

Paradigm-Changing Therapeutics

We strive to identify extraordinary biotech companies with the opportunity of offering both substantial risk-adjusted returns.

25+ Years of Investing Experience

Marc Schneidman, Founder & CIO, has over 20 years of dedicated investing experience across the biotechnology universe.

We Translate Opportunities Into Scientific Breakthroughs

*Securities highlighted or discussed above have been selected to illustrate Aquilo Capital Management, LLC’s (“Aquilo”) investment approach and/or market outlook and are not intended to represent the performance of Aquilo’s clients or indicator for how Aquilo’s clients have performed or may perform in the future. Each listed security was selected solely for this purpose and has not been selected on the basis of performance or any performance-related criteria. The securities discussed herein do not represent an entire portfolio and in the aggregate may only represent a small percentage of a clients’ holdings. Aquilo’s clients’ portfolios are actively managed and securities discussed may or may not be held in such portfolios at any given time. Nothing on this webpage shall constitute a recommendation or endorsement to buy or sell any security or other financial instrument referenced herein.